Search Beyond News…

Extension of the claims deadline in Canada’s Rexulti class action settlement prolongs the administration of a CAD 4.75 million fund for eligible patients

Executive summary: The deadline for submitting claims in the national Rexulti class action settlement in Canada has been extended. A longer filing window allows more eligible patients and estates to participate, potentially affecting the final distribution of the CAD 4.75 million settlement fund and highlighting continued litigation risk for the drug’s manufacturer.

Who is involved: Claimants who were prescribed Rexulti in Canada, their estates and family members, the settlement trustee, Otsuka Pharmaceutical, and the Quebec Superior Court.

Likely next: Claimants must submit their claims by the new deadline; the trustee will review submissions and distribute the settlement fund accordingly; any objections or appeals would be heard by the court.

The Quebec Superior Court approved the Rexulti settlement in November 2025, establishing a fund to compensate individuals who took the antidepressant. Extending the deadline gives more claimants time to file, which may increase the number of validated claims and the administrative burden on the settlement trustee. The move underscores the ongoing legal exposure of Otsuka Pharmaceutical, the drug’s marketer, in the Canadian market.

Timeline

Analysis — what this means

Sectors affected

Regulatory implications

Historical parallels

Sources

Related cases

Browse the full archive →